Immunology / Virology & Vaccines

Vaccine production
#Collaboration #Immunology / Virology & Vaccines #Lifera #Manufacturing #Sanofi #Saudi Arabia

Partners agree to boost vaccine accessibility in Saudi Arabia

Saudi Arabian company Lifera is partnering with Sanofi and Arabio to strengthen local manufacturing of vaccines in Saudi Arabia. Under the terms of the Memorandum of Understanding (MOU), Lifera, Sanofi and Arabio will explore opportunities for collaboration to help advance Saudi Arabia’s vaccines localisation strategy through… Read More

#News

Chickens
#Genetics / genomics #Immunology / Virology & Vaccines #Influenza #Pandemic prevention

Human gene that defends against avian flu discovered

New research has found a key human gene responsible for blocking most avian flu viruses from spilling over into people. The international study into the pandemic potential of avian flu, which is led by scientists at the MRC-University of Glasgow Centre for Virus Research (CVR), identified… Read More

#Editor's Choice #News

Gram positive cocci in chain bacteria, Streptococcus, a type of bacteria
#Biotechnology #Clinical trials #Group B Streptococcus #Immunology / Virology & Vaccines #MinervaX #Streptococcus

Full enrolment for Phase I clinical trial of Group B streptococcus  

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has completed enrolment and initial dosing in its Phase I clinical vaccine trial in older adults. The trial is taking place at CEVAC (Centre for Vaccinology), Ghent University, Belgium.  GBS is most… Read More

#News

Respiratory syncytial virus
#FDA #GSK #Immunology / Virology & Vaccines #Pfizer #Respiratory syncytial virus

GSK faces RSV vaccine threat from rival Pfizer  

An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData.  GSK received approval by the European Commision (EC) for its vaccine Arexvy, which targets the prevention of lower respiratory tract infections (LRTI) caused by RSV in… Read More

#News #Regulatory #Trending News

Vaccine production
#Emory University #Immunology / Virology & Vaccines #Pandemic prevention #Partnership #University of Queensland

Brisbane-Atlanta partnership focuses on pandemic response

The University of Queensland (UQ), Australia, and Emory University in Atlanta, US, have committed to scaling up their collaboration to focus on pandemic preparedness and regional disease prevention. UQ Vice-Chancellor Professor Deborah Terry said the Brisbane-Atlanta partnership will bring together world-class researchers to accelerate the development… Read More

#News

RNA strand
#Evotec #Funding #Immunology / Virology & Vaccines #Pandemic prevention #RNA #RNA sequencing

Grant supports discovery of RNA-targeting Henipavirus therapeutics

Evotec has received a $1.7 million grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing. Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. Henipavirus is a genus of zoonotic viruses that… Read More

#News

#Biopharmaceuticals #Immunology / Virology & Vaccines #Investment #invoX Pharma #mRNA #mRNA-based vaccines #Next generation sequencing #Sino Biopharmaceutical

pHion to progress its lead program into the clinic 

invoX Pharma, a UK-based wholly-owned subsidiary of Sino Biopharmaceutical, with an advancing pipeline of innovative products, has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.   pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. The company’s proprietary… Read More

#Business & Investment #News

Vaccine
#FDA #Immunology / Virology & Vaccines #Pfizer #Phase III trial #Respiratory syncytial virus

FDA approves first vaccine for respiratory syncytial virus

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. Abrysvo is unadjuvanted and composed of two preF proteins selected to optimise protection against RSV A and B strains and… Read More

#News #Trending News

Influenza virus
#Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines #National Institute of Allergy and Infectious Diseases #Phase I trial

mRNA universal influenza vaccine enters clinical trials

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase I trial will test the experimental vaccine,… Read More

#News #Trending News

Older adult receiving vaccine
#Bacteria #Immunology / Virology & Vaccines #MinervaX #Phase I trial #Vaccine candidate

Trials of Group B Streptococcus vaccine extended to older adults

Danish biotech MinervaX has launched the first Phase I clinical study in older adults of its novel Group B Streptococcus (GBS) vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. GBS is a global unmet medical burden and can cause serious illness in people of all… Read More

#News

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines

Tuesday 18 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Tuesday 17 April at AACR 2023, from AI and mathematical oncology to winners of the AACR James S Ewing-Thelma B Dunn Award for Outstanding Achievement in Pathology in Cancer Research. Clinical announcements Promising results for olaparib plus ceralasertib Today, results from the Phase… Read More

#News

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines

Monday 17 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Monday 16 April at AACR 2023, from promising trial results for colorectal cancer patients to updates on Biden’s Cancer Moonshot initiative. Clinical announcements  Data on colorectal cancer patients with African ancestry Today, data presented at the AACR Annual Meeting showed that genomic… Read More

#News

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines #mRNA

Sunday 16 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Sunday 16 April at AACR 2023, from promising trial results for a personalised mRNA-based cancer vaccine to winners of lifetime achievement awards. Opening plenary session Sunday’s opening plenary session borrowed its name from the Annual Meeting theme, “Advancing the Frontiers of Cancer Science… Read More

#News

Malaria vaccine
#Africa #Immunology / Virology & Vaccines #Malaria #Regulatory #Serum Institute of India #University of Oxford #Vaccines

Ghana vaccine approval a ‘critical step’ in combatting malaria

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. R21/Matrix-M was developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SIIPL), leveraging Novavax’s… Read More

#News #Regulatory #Trending News

#Cancer immunotherapy #Immunology / Virology & Vaccines #Moderna #mRNA #mRNA-based vaccines #Tumour biology

Vaccine for the ‘previously undruggable’ just a decade away 

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 20301. The pharmaceutical firm also provided promising updates on mRNA-4157/V940, which targets different tumour types, at Moderna’s Vaccines Day on 24 March 20232.   The… Read More

#News